Home  »  Science   »  Amneal Pharmaceuticals Inc. (NYSE: AMRX) Surprises...

Amneal Pharmaceuticals Inc. (NYSE: AMRX) Surprises Wall Street With 0.88% Stock Price Gain

Amneal Pharmaceuticals Inc. (NYSE:AMRX) has a beta value of 1.28 and has seen 1.21 million shares traded in the last trading session. The company, currently valued at $698.06M, closed the last trade at $2.29 per share which meant it gained $0.02 on the day or 0.88% during that session. The AMRX stock price is -161.57% off its 52-week high price of $5.99 and 6.11% above the 52-week low of $2.15. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.17 million shares traded. The 3-month trading volume is 1.06 million shares.

Amneal Pharmaceuticals Inc. (NYSE:AMRX) trade information

Sporting 0.88% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, 09/20/22 when the AMRX stock price touched $2.29 or saw a rise of 3.38%. Year-to-date, Amneal Pharmaceuticals Inc. shares have moved -52.19%, while the 5-day performance has seen it change 3.15%. Over the past 30 days, the shares of Amneal Pharmaceuticals Inc. (NYSE:AMRX) have changed -15.50%. Short interest in the company has seen 3.99 million shares shorted with days to cover at 2.64.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Amneal Pharmaceuticals Inc. (AMRX) estimates and forecasts

Figures show that Amneal Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -43.46% over the past 6 months, with this year growth rate of -14.12%, compared to 11.30% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are -14.30% and 16.70% for the next quarter. Revenue growth from the last financial year stood is estimated to be 5.30%.

7 analysts offering their estimates for the company have set an average revenue estimate of $564.15 million for the current quarter. 7 have an estimated revenue figure of $582.87 million for the next quarter concluding in Dec 2022.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 15.00% over the past 5 years. Earnings growth for 2022 is a modest 155.00% while over the next 5 years, the company’s earnings are expected to decrease by -12.10%.

AMRX Dividends

Amneal Pharmaceuticals Inc. is expected to release its next earnings report between November 01 and November 07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Amneal Pharmaceuticals Inc. (NYSE:AMRX)’s Major holders

Insiders own 10.82% of the company shares, while shares held by institutions stand at 67.60% with a share float percentage of 75.81%. Investors are also buoyed by the number of investors in a company, with Amneal Pharmaceuticals Inc. having a total of 218 institutions that hold shares in the company. The top two institutional holders are Fosun International Ltd with over 21.52 million shares worth more than $49.28 million. As of Jun 29, 2022, Fosun International Ltd held 14.21% of shares outstanding.

The other major institutional holder is Tpg Group Holdings (sbs) Advisors, Inc., with the holding of over 16.21 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $37.13 million and represent 10.71% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.64% shares in the company for having 3.99 million shares of worth $9.14 million while later fund manager owns 3.48 million shares of worth $7.96 million as of Jun 29, 2022, which makes it owner of about 2.30% of company’s outstanding stock.

Leave a Comment

Your email address will not be published.

On Key

Related Posts